NumFin

Abeona Therapeutics Inc.

Sümbol: ABEO

NASDAQ

3.26

USD

Turuhind täna

  • -1.5375

    P/E suhe

  • 0.0712

    PEG suhe

  • 89.18M

    MRK Cap

  • 0.00%

    DIV tootlus

Abeona Therapeutics Inc. (ABEO) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Abeona Therapeutics Inc. (ABEO) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 1.417 M, mis on 0.659 % gowth. Kogu perioodi keskmine brutokasum on -0.59 M, mis on 0.579 %. Keskmine brutokasumi suhtarv on -1.126 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.704 %, mis on võrdne -1.722 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Abeona Therapeutics Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.003. Käibevara valdkonnas on ABEO aruandlusvaluutas 55.737. Märkimisväärne osa neist varadest, täpsemalt 52.564, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.008%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 4.402 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.292%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 14.826 aruandlusvaluutas. Selle aspekti aastane muutus on -0.446%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 2.444, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

183.4552.652.145
95
129.3
85
137.8
69.1
40.1
11.5
0.4
0.4
2.5
7
0.6
2.7
6.9
4.4
0.5
2.3
2.6
9.8
20.1
25.8
0.9
1.5
0.4
4.4
1.9

balance-sheet.row.short-term-investments

153.0337.837.912.1
82.4
0
66.2
0
0
0
0
0
0
0
0
0
0
6.8
3.2
0.1
0.5
1.9
8.3
12.7
17.4
0
0
0
0
0

balance-sheet.row.net-receivables

10.92.40.23
0
0
0.1
0.1
0.1
0.1
0
0.1
0.8
0.3
1
0
0.8
1
0.4
4.5
0.8
1.2
1.3
0.2
0.4
0.1
0
0
0
0

balance-sheet.row.inventory

1.0100.30
0
0
0
0
0
0
0
0
0.2
0.2
0
0
0
0
0
0.2
0.1
0.1
0.5
0
0
0
0
0
0
0.1

balance-sheet.row.other-current-assets

4.520.70.47.4
2.7
3.1
3.8
2.7
0.2
0.3
0
0.1
0.3
0.4
0.1
0
0.1
0.4
0.3
0
1.1
0.9
0.9
0.6
0.1
0.1
0
0.1
0.2
0.1

balance-sheet.row.total-current-assets

199.8855.753.155.4
97.7
132.4
88.9
140.6
69.4
40.6
11.6
0.6
1.7
3.3
8.1
0.7
3.5
8.3
5
5.2
4.3
4.8
12.4
20.9
26.4
1.1
1.5
0.5
4.6
2.1

balance-sheet.row.property-plant-equipment-net

36.48811.121.7
18.4
21.2
9.4
1.4
0.7
0.3
0
0
0
0.1
0
0.1
0.1
0.1
0.2
0.3
1
1
0.7
0.5
0.1
0.1
0.2
0.4
0.3
0

balance-sheet.row.goodwill

0000
32.5
32.5
32.5
32.5
32.5
32.5
0
0
0
0
0
0
0
0
0
0
1.9
0
1.9
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0001.4
1.5
36.2
43
4
8.4
6.6
5
0
0
0.4
0.6
0.8
0.5
0.7
0.9
1.1
2.4
4.9
3.4
2.6
3
3.3
0.4
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0001.4
34
68.6
75.5
36.4
40.9
39.1
5
0
0
0.4
0.6
0.8
0.5
0.7
0.9
1.1
4.3
4.9
5.3
2.6
3
3.3
0.4
0.5
0
0

balance-sheet.row.long-term-investments

0000.9
1
1.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

000-0.9
-1
-1.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.620.301.1
1.1
1.1
0.6
0.4
0.1
0.1
0
0
0
0.1
0
0.1
0.1
0
0.3
0.6
1.5
1.1
1.1
1.4
1
0.2
0.3
0.1
0
0

balance-sheet.row.total-non-current-assets

37.18.311.124.2
53.5
91
85.5
38.2
41.6
39.5
5
0
0
0.5
0.7
0.9
0.7
0.9
1.4
2.1
6.8
7
7.1
4.6
4.1
3.5
0.9
1
0.3
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

236.986464.279.6
151.2
223.4
174.4
178.8
111.1
80.1
16.6
0.6
1.7
3.8
8.8
1.6
4.3
9.1
6.4
7.2
11.1
11.8
19.5
25.5
30.5
4.6
2.4
1.4
4.9
2.1

balance-sheet.row.account-payables

10.781.91.84.3
4.7
3.8
6.1
2.4
3.7
0.9
1.9
0.9
2
1.7
3
4.1
2
1.8
1.2
2.9
2.1
1.8
2.5
1.5
1.2
0.7
0.4
0
0
0.1

balance-sheet.row.short-term-debt

6.0311.81.8
2
1.7
10
0
0
0
0.4
0
4.1
2.8
5.5
0
0
0.1
8.8
0.1
8.4
0.3
0.8
0.1
0
0
0.1
0.2
0.2
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

18.354.45.97.6
6.7
6.3
20
0
0
4
4
0
0
0
0
5.5
5.5
5.5
5.5
7.6
5.7
14
14.2
0.5
0
0
0
0.1
0.2
0

Deferred Revenue Non Current

0000
0
0
0
3.1
3.7
4.3
4.9
5.2
2.7
3.3
4.4
4.7
2.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

13.7310.64.210.2
34.9
32.9
3.9
0
4
0
0
7.5
0.2
7.4
5.4
4.2
2.8
0.1
0.6
0.7
0.3
0.3
0.3
0.3
0.3
0.1
0
0.5
0.5
0.3

balance-sheet.row.total-non-current-liabilities

133.3635.829.711.6
6.7
6.3
20
3.1
3.7
10.9
8.9
6.4
12.2
9.2
15.3
19.9
7.7
6.4
5.5
7.6
5.7
14
14.2
14
13.5
0
0.1
0.1
0.2
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

23.394.47.69.4
7
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
0.2
0

balance-sheet.row.total-liab

172.0349.237.528.2
48.6
45
40.4
8.7
12
12.3
11.8
15.4
18.8
21.4
29.6
28.6
12.7
8.5
16.3
11.4
17.8
17.6
19
16.4
15.5
1
0.6
0.8
0.9
0.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
2.470002506530004e+24
2.3900023760000038e+24
1.910002301530004e+24
1.3200021573500012e+22
7.000012748200011e+37
8672
0
0
0
0
0
0.2
0.1
0
0
0
0
0

balance-sheet.row.common-stock

0.910.30.21.5
1
0.8
0.5
0.5
0.4
0.3
0.2
0.3
0.2
0.2
0.2
0.1
0.1
0
0
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0
1.3
1.3
0.3

balance-sheet.row.retained-earnings

-2908-749.5-695.3-655.6
-570.7
-486.5
-410.2
-359.8
-332.5
-310.6
-296.1
-266.4
-268
-255.4
-251.1
-241.8
-134.9
-114.3
-77.7
-66.2
-64.5
-54.2
-47.3
-37.9
-31.9
-26.5
-23.1
-19.7
-15.3
-39

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.33-0.1-0.10
0
0
-1.6
-0.4
-0.2
0
0
0
-0.9
-0.8
-0.9
-1.3200021573500012e+22
-7.000012748200011e+37
-1
-1
-1
-1.4
-1.3
-1.3
-1.2
-1
-0.9
-0.8
0
0
0

balance-sheet.row.other-total-stockholders-equity

2972.36764.2722705.6
672.3
664.1
545.3
529.8
431.3
378
300.7
251.4
-2.470002506530004e+24
-2.3900023760000038e+24
-1.910002301530004e+24
-27
-8.4
-8556
68.8
62.8
59
49.6
49
47.8
47.7
30.9
25.7
19
18.1
40.4

balance-sheet.row.total-stockholders-equity

64.9514.826.851.4
102.6
178.4
134
170.1
99.1
67.7
4.8
-14.8
-17.1
-17.6
-20.8
-27
-8.4
0.7
-9.9
-4.2
-6.7
-5.8
0.5
9.1
15
3.6
1.8
0.6
4.1
1.7

balance-sheet.row.total-liabilities-and-stockholders-equity

236.986464.279.6
151.2
223.4
174.4
178.8
111.1
80.1
16.6
0.6
1.7
3.8
8.8
1.6
4.3
9.1
6.4
7.2
11.1
11.8
19.5
25.5
30.5
4.6
2.4
1.4
4.9
2.1

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

64.9514.826.851.4
102.6
178.4
134
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

236.98---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

153.0337.837.912.1
82.4
1.1
66.2
0
0
0
0
0
0
0
0
0
0
6.8
3.2
0.1
0.5
1.9
8.3
12.7
17.4
0
0
0
0
0

balance-sheet.row.total-debt

24.395.47.69.4
8.7
8
30
0
0
4
0.4
0
0
2.8
5.5
5.5
5.5
5.6
14.3
7.7
14.1
14.4
15
0.6
13.5
0
0.1
0.3
0.3
0.4

balance-sheet.row.net-debt

-6.04-9.4-6.6-23.6
-3.9
-121.3
11.3
-137.8
-69.1
-36.1
-11.1
-0.4
-0.4
0.3
-1.5
4.9
2.8
5.4
13.1
7.4
12.3
13.6
13.6
-6.9
5.1
-0.8
-1.4
-0.1
-4.1
-1.5

Rahavoogude aruanne

Abeona Therapeutics Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.144 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 37.21, mis tähistab 49.718 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 2.04 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 208000.000. See on -1.009 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 3.2, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -0.15, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

cash-flows.row.net-income

-54.19-54.2-39.7-84.9
-84.2
-76.3
-56.7
-27.3
-21.9
-14.5
-26.8
4.4
-10.5
-2.5
-7.5
-17.3
-17.2
-21.7
-12.9
-1.7
-10.2
-6.9
-9.4
-6
-5.4
-3.3
-3.4
-4.4
-11.5
0.3

cash-flows.row.depreciation-and-amortization

3.23.24.64.5
5.6
8.7
2.4
0.7
0.8
0.6
0
0
0.4
0.2
0.2
0.3
0.3
2.6
7.1
1.6
1.1
0.9
0.7
0.6
0.5
0.3
0.2
0.2
0.1
0

cash-flows.row.deferred-income-tax

7.92-11.2030.7
32.9
0
-1.3
-1.4
0
0
23.1
-8.3
5.8
-6.3
0.7
0
0
-77
0
-42
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

4.774.83.18.9
8.2
8.2
8.9
5.9
4.8
4.4
1.3
0.4
0.4
1.1
1
0.8
0
77
0
42
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-1.79-1.8-5.9-18.3
1.6
-3.6
7
-2.1
-0.2
-6.1
0.4
3.1
-0.2
-0.7
-2.2
3.7
0.7
1.5
3
3
0
-0.4
-0.7
0.1
0.3
-0.2
1.2
-0.1
0
0.3

cash-flows.row.account-receivables

-0.1-23-3
0
0.1
0
0
0
-0.1
0
0.8
-0.5
685
-982
111
-747
4129
0
622
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-0.5800-16.1
0
-0.1
-1
-2.6
0.2
-0.3
0.7
0.2
0
-0.2
1581.1
-479
570.4
-2476.7
0
0.1
0.1
0.4
-0.5
0
0
0
0
0
0
0

cash-flows.row.account-payables

2.042-10.50.8
-2.2
-1.7
7.7
-1.3
2.8
-1.2
0
-1.2
0.6
53
-601
369
176
-1657
0
490
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-3.15-1.81.60
3.8
-1.8
0.3
1.7
-3.2
-4.5
-0.3
3.3
-0.2
-738.5
-0.3
2.7
1.4
6.2
3
-1109.1
-0.1
-0.7
-0.2
0.1
0.3
-0.2
1.2
-0.1
0
0.3

cash-flows.row.other-non-cash-items

3.0822.2-5.5-6.6
0.9
0.1
0.7
1.3
3.4
5.3
0.3
0.3
0.1
0.6
0.9
10.4
9.7
22.4
0.9
-10.2
0.1
0.1
0.8
0
0.4
0
-1.2
0.8
8.7
0

cash-flows.row.net-cash-provided-by-operating-activities

-37.01000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.33-0.3-0.1-4.2
-1.3
-6.5
-19.5
-0.9
-0.5
-0.3
0
0
0
0
0
0
-0.1
0
0
0
-0.2
-0.5
-0.4
-0.4
-0.1
0
-0.1
0
0
0

cash-flows.row.acquisitions-net

-2.340.21.74.2
1.3
0
19.5
0
0
3.7
0
0
0
0
0
0
-65
0
0
0
0
0
-1.3
0
0
-0.1
0
0
0
0

cash-flows.row.purchases-of-investments

-51.64-51.6-78.2-20.2
-170.5
0
-136.1
0
0
0
0
0
0
0
0
0
0
-3.6
-3.1
0
0
0
0
0
-17.4
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

51.975252.690.4
88.1
66.5
70.5
0
0
0
0
0
0
0
0
0
0
0
0
0.4
1.4
6.5
4.4
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

14.1100-4.2
-1.3
0
-19.5
0
0
0
0
0
0
0
0
0
65
0
0.6
9.4
0
0
0
4.1
0
0
0
-0.2
0
0

cash-flows.row.net-cash-used-for-investing-activites

0.210.2-2466.1
-83.7
60
-85.1
-0.9
-0.5
3.4
0
0
0
0
0
0
-0.1
-3.6
-2.5
9.7
1.2
6
2.7
3.7
-17.5
-0.1
-0.1
-0.2
0
0

cash-flows.row.debt-repayment

0000
-1.8
0
0
0
0
-0.4
0
0
-2.8
-2.8
0
0
-0.1
0
0
0
0
0
0
0
0
0
0
-0.2
-0.1
0

cash-flows.row.common-stock-issued

1687.6437.24725.5
0
112.9
0
86.2
42.2
31.4
12.3
0
4654
5.8
13.1
0
2444
0
0
0.6
9.3
0.3
0
0
18.6
2.8
4.6
0
5.5
0

cash-flows.row.common-stock-repurchased

-0.180-26.30
0
0
0
0
0
0
0
0
-4335
2750
0
0
-2425
0
0
0
0
0
0
0
-0.8
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
-11579
0
-319
-271
-168
-82
-19
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-1650.58-0.122.5-0.6
3.7
1
5.5
6.2
0.3
4.6
11579.4
0
4.7
-2479
168.2
82.2
2.5
7.3
5.3
-4.4
-0.3
-0.7
-0.1
0.6
11.5
-0.1
-0.2
0
1.7
-0.1

cash-flows.row.net-cash-used-provided-by-financing-activities

37.0637.143.224.9
1.9
113.9
5.5
92.4
42.5
35.7
12.7
0
1.9
3.1
13.3
0.2
2.4
7.4
5.3
-3.8
9
-0.4
-0.1
0.6
29.3
2.7
4.4
-0.2
7.1
-0.1

cash-flows.row.effect-of-forex-changes-on-cash

1646.74000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0.260.3-24.325.3
-116.8
111.1
-118.7
68.6
29
28.6
11.1
0
-2.1
-4.6
6.4
-2.1
-4.3
8.7
0.8
-1.4
1
-0.7
-6
-1
7.5
-0.6
1.1
-4
4.4
0.6

cash-flows.row.cash-at-end-of-period

31.4414.814.638.8
13.6
130.4
19.3
137.8
69.1
40.1
11.5
0.4
0.4
2.5
7
0.6
2.7
9.8
1.2
0.3
1.8
0.7
1.4
7.4
8.4
0.9
1.5
0.4
4.4
1.9

cash-flows.row.cash-at-beginning-of-period

31.1914.638.813.6
130.4
19.3
138
69.1
40.1
11.5
0.4
0.4
2.5
7
0.6
2.7
6.9
1.2
0.3
1.8
0.7
1.4
7.4
8.4
0.9
1.5
0.4
4.4
0
1.3

cash-flows.row.operating-cash-flow

-37.01-37-43.5-65.7
-35
-62.8
-39.1
-22.9
-13
-10.4
-1.6
0
-4
-7.6
-6.9
-2.2
-6.6
4.8
-2
-7.3
-9.1
-6.4
-8.6
-5.3
-4.3
-3.2
-3.2
-3.6
-2.7
0.7

cash-flows.row.capital-expenditure

-0.33-0.3-0.1-4.2
-1.3
-6.5
-19.5
-0.9
-0.5
-0.3
0
0
0
0
0
0
-0.1
0
0
0
-0.2
-0.5
-0.4
-0.4
-0.1
0
-0.1
0
0
0

cash-flows.row.free-cash-flow

-37.34-37.3-43.6-69.8
-36.4
-69.3
-58.6
-23.8
-13.5
-10.7
-1.6
0
-4
-7.6
-6.9
-2.3
-6.7
4.8
-2
-7.3
-9.3
-6.8
-9
-5.7
-4.4
-3.3
-3.3
-3.6
-2.7
0.7

Kasumiaruande rida

Abeona Therapeutics Inc. tulud muutusid võrreldes eelmise perioodiga 1.475%. ABEO brutokasum on teatatud 0.3. Ettevõtte tegevuskulud on 48.5, mille muutus võrreldes eelmise aastaga on 4.935%. Kulud amortisatsioonikulud on 3.2, mis on 4.591% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 48.5, mis näitab 4.935% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.065% kasvu võrreldes eelmise aastaga. Tegevustulu on -48.2, mis näitab 0.065% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.704%. Eelmise aasta puhaskasum oli -54.19.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

3.53.51.43
10
0
3
0.8
0.9
1
0.9
2
4.4
1.8
0.5
0.4
0.3
0.1
0
0
0.5
1.3
1.1
0.2
0.1
0
0.1
0.4
0.2
2.9

income-statement-row.row.cost-of-revenue

3.23.20.54.5
30.1
8.7
0
0
0
0
0
0.1
0.3
1.2
0.1
0
0
0
0
0
0.2
0.3
0.1
0
0
0
0
0.6
8.3
0

income-statement-row.row.gross-profit

0.30.31-1.5
-20.1
-8.7
3
0.8
0.9
1
0.9
1.9
4.1
0.6
0.3
0.4
0.3
0.1
0
0
0.3
1
1
0.2
0.1
0
0.1
-0.1
-8.1
2.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

31.09---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-1.59---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

2.942.90.13.3
4.6
7.8
2.4
0.7
0.8
0.6
3.7
4.8
0.4
4.3
0.2
0.3
0.3
4.4
3.1
6.8
4
3.1
2.7
2.4
2.2
1.8
1.7
1.9
2.1
1.4

income-statement-row.row.operating-expenses

48.548.546.260.4
58.5
77.1
61.2
28.7
24.8
19.6
4.1
5.7
8.5
8.5
8.1
10
17.2
7
5.2
9.6
9.4
9.2
9.7
6.6
6.2
3.4
3.5
4.4
3.5
2.6

income-statement-row.row.cost-and-expenses

51.751.746.760.4
58.5
77.1
61.2
28.7
24.8
19.6
4.1
5.8
8.7
9.7
8.2
10
17.2
7
5.2
9.6
9.6
9.5
9.8
6.6
6.2
3.4
3.5
5
11.8
2.6

income-statement-row.row.interest-income

2.122.10.40.1
1.3
1.2
1.5
0.5
2
4
0
0.3
0.2
1.3
2
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0.420.40.73.7
4.1
0.4
0
0
0
0
0.6
0.3
0.6
1
0.6
0.5
0.5
3.5
7.4
2.1
1.4
1.3
1.3
1.2
0.3
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-1.59---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-5.99-65.64.9
-2.8
0.8
1.5
0.5
2
4
-23.1
8.3
-5.8
5
-1.2
-7.2
-0.3
-11.6
-1.1
-1.9
-1.2
1.3
-0.7
0.3
0.6
0
0
0.1
0.2
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

2.942.90.13.3
4.6
7.8
2.4
0.7
0.8
0.6
3.7
4.8
0.4
4.3
0.2
0.3
0.3
4.4
3.1
6.8
4
3.1
2.7
2.4
2.2
1.8
1.7
1.9
2.1
1.4

income-statement-row.row.total-operating-expenses

-5.99-65.64.9
-2.8
0.8
1.5
0.5
2
4
-23.1
8.3
-5.8
5
-1.2
-7.2
-0.3
-11.6
-1.1
-1.9
-1.2
1.3
-0.7
0.3
0.6
0
0
0.1
0.2
0

income-statement-row.row.interest-expense

0.420.40.73.7
4.1
0.4
0
0
0
0
0.6
0.3
0.6
1
0.6
0.5
0.5
3.5
7.4
2.1
1.4
1.3
1.3
1.2
0.3
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

3.23.20.635.8
38.8
9.9
2.4
0.7
0.8
0.6
0
0
0.4
0.2
0.2
0.3
0.3
2.6
7.1
1.6
1.1
0.9
0.7
0.6
0.5
0.3
0.2
0.2
0.1
0

income-statement-row.row.ebitda-caps

-45---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-48.2-48.2-45.3-89.8
-81.4
-77.1
-58.2
-27.8
-23.9
-18.5
-3.1
-3.8
-4.3
-7.9
-7.8
-9.7
-16.9
-6.9
-5.2
-9.6
-9.1
-8.2
-8.7
-6.3
-6.1
-3.3
-3.4
-4.5
-11.6
0.3

income-statement-row.row.income-before-tax

-54.19-54.2-39.7-84.9
-84.2
-76.3
-56.7
-27.3
-21.9
-14.5
-26.8
4.4
-10.5
-2.5
-9
-16.8
-17.2
-21.9
13.4
-11.6
-10.2
-6.9
-9.4
-6
-5.4
-3.3
0
-4.4
-11.5
0.3

income-statement-row.row.income-tax-expense

00-7.93.7
4.1
0.4
1.5
0.5
2
4
0.6
0.3
0.6
0
-0.2
7.7
0.2
-0.1
-0.2
-4.1
0
0
0
0
0
0
0
-0.1
-0.2
0

income-statement-row.row.net-income

-54.19-54.2-31.8-88.6
-88.3
-76.7
-56.7
-27.3
-21.9
-14.5
-26.8
4.4
-10.5
-2.5
-7.5
-17.3
-17.2
-21.9
-12.9
-1.7
-10.2
-6.9
-9.4
-6
-5.4
-3.3
-3.4
-4.4
-11.5
0.3
Sarnased aktsiad
Sind võib huvitada ka:
MRVI
Maravai LifeSciences Holdings, Inc..
7.7 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0361 USD
NASDAQ
T5O.DE
CytoTools AG.
0.488 EUR
XETRA
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK
ARQT
Arcutis Biotherapeutics, Inc..
8.47 USD
NASDAQ

Korduma kippuv küsimus

Mis on Abeona Therapeutics Inc. (ABEO) koguvara?

Abeona Therapeutics Inc. (ABEO) koguvara on 64001999.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.086.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -1.461.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -15.482.

Mis on ettevõtte kogutulu?

Kogutulu on -13.771.

Mis on Abeona Therapeutics Inc. (ABEO) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -54188000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 5400000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 48502000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 14811000.000.